Basic Flunarizine Information

• INN (International Nonproprietary Name): Flunarizine (Flunarizine hydrochloride).
• Brand Names Available In United Kingdom: Sibelium® (withdrawn; rarely available via import for individual patients).
• ATC Code: N07CA03.
• Forms & Dosages: Tablet 5 mg and 10 mg orally; capsules 5 mg and 10 mg are less common.
• Manufacturers In United Kingdom: Not specified.
• Registration Status In United Kingdom: Withdrawn from routine supply; access is typically by importation or unlicensed “specials”.
• OTC / Rx Classification: Prescription-only (Rx) in markets where it is approved.

Key Findings From Recent Trials

Major 2022–2025 Studies

What Does The Latest Evidence Say About Effectiveness In Migraine And Vertigo?

High-quality, large-scale randomised controlled trials of flunarizine in 2022–2024 remain scarce.

Most of the contemporary evidence comes from older RCTs, observational cohorts, specialist service audits and systematic reviews.

Pre-2020 meta-analyses demonstrated that flunarizine was superior to placebo for migraine prophylaxis with a modest reduction in monthly migraine days.

Smaller trials historically showed consistent benefit for vertigo symptom control versus placebo or cinnarizine.

From 2020 to 2024 the trend has been toward pragmatic cohort data and specialist vestibular service audits rather than new placebo‑controlled RCTs.

These newer cohorts report meaningful reductions in vestibular migraine frequency and severity among refractory patients who failed first‑line preventives.

Main Outcomes

Which Patients Seem To Benefit Most?

Patients with vestibular migraine and those with refractory chronic migraine often report the largest clinical benefit in audits and cohort series.

Typical outcomes include fewer migraine days per month and reduced intensity or duration of vertigo attacks after several weeks of treatment.

Clinical response commonly appears within 6–12 weeks and is assessed at 2–3 months in routine practice.

If no benefit is observed by six months clinicians generally stop the drug.

Safety Observations

Are There New Safety Concerns?

Safety trends dominate the recent literature and audits.

Pooled safety observations confirm increased risk of depressive symptoms, sedation and extrapyramidal syndromes—particularly with prolonged use and in older adults.

These signals have prompted tighter prescribing caution in UK clinical practice.

The brand Sibelium® is largely unavailable in the UK and clinicians sometimes use authorised importation for carefully selected patients after governance review.

There remains an evidence gap for contemporary, placebo‑controlled RCTs that are powered for patient‑centred outcomes and long‑term safety endpoints, especially in vestibular migraine.

Clinical Mechanism Of Action

Layman’s Explanation

How Does Flunarizine Reduce Migraines And Vertigo?

Flunarizine reduces the likelihood of migraine attacks and dampens vertigo by stabilising neuronal excitability and reducing abnormal calcium influx into nerve cells.

Patients often notice fewer attacks and less intense vertigo after a few weeks of nightly dosing.

Scientific Breakdown

What Happens At A Cellular Level?

Flunarizine is a diphenylpiperazine derivative that acts primarily as a selective blocker of voltage‑dependent calcium channels.

It limits cellular calcium entry during depolarisation, which stabilises hyperexcitable neurons implicated in migraine and vestibular dysfunction.

Additional pharmacology includes antihistaminic activity and mild antidopaminergic effects, which contribute to sedation and the small but important risk of movement disorders.

Receptor Targets

Which Receptors Does It Affect?

Primary receptor targets include L‑type voltage‑dependent calcium channels, H1 histamine receptors (antagonism) and dopamine D2 receptors (weak antagonism).

The D2 antagonism provides the mechanistic basis for parkinsonism and other extrapyramidal symptoms in susceptible patients.

Pharmacokinetics (Summary)

How Is It Absorbed And Cleared?

Oral absorption of flunarizine is good and hepatic metabolism predominates.

Active metabolites are formed and elimination is slow, which supports once‑daily nocturnal dosing to reduce daytime sedation.

Clinical implication: the mechanism explains benefit in both migraine and vertigo, and also anticipates sedation, weight gain and movement disorder risks.

Scope Of Approved And Off‑Label Use

United Kingdom Approvals

Is Flunarizine Licensed In The UK?

Sibelium® has been withdrawn and is not routinely available in the United Kingdom.

Where clinicians consider flunarizine, access is usually by importation or an unlicensed “special” for individual patients after a documented risk–benefit assessment and local governance sign‑off.

Internationally flunarizine (ATC N07CA03) is licensed in several European countries and in Canada for migraine prophylaxis and vertigo.

Notable Off‑Label Trends

How Do Clinicians Use It Outside Approved Indications?

Specialist use continues in vestibular migraine and refractory chronic migraine when first‑line preventives are ineffective or contraindicated.

Rare specialist use as adjunctive therapy in epilepsy is reported, but this is exceptional and requires close specialist oversight.

In the UK off‑label use requires clear informed consent, documented monitoring and heightened vigilance for adverse events such as depression and parkinsonism.

Typical treatment trials are 2–3 months with discontinuation if no benefit by six months.

Dosage Strategy

General Dosing

What Dose Should Most Adults Start On?

Standard adult initiation is 10 mg once daily at night, with the option to reduce to 5 mg if adverse effects occur or for elderly patients.

Tablets are commonly supplied as 5 mg and 10 mg strengths.

Treatment effect is usually assessed after 2–3 months, and lack of benefit by six months should prompt discontinuation.

Some clinicians use periodic drug holidays—for example two months on and one month off—to reduce cumulative adverse effects in long‑term use.

Condition‑Specific Dosing

Are Dose Recommendations Different For Migraine Versus Vertigo?

Migraine Prophylaxis: The usual starting and maintenance dose is 10 mg nightly, with reduction to 5 mg for older adults or if sedation or depressive symptoms occur.

Vertigo (Central/Peripheral): Similar dosing of 5–10 mg nightly is used, with gradual titration to effect and several weeks required for response in vestibular migraine.

Epilepsy Adjunct: Rare and specialist‑led; dosing is tailored and monitoring is intensive because of possible effects on seizure threshold.

Hepatic Impairment And Elderly: Start low (5 mg) and monitor carefully given hepatic metabolism and increased extrapyramidal risk in older adults.

Safety Protocols

Contraindications

Who Must Not Take Flunarizine?

Absolute contraindications include a history of depressive illness or active depression, Parkinson’s disease or other extrapyramidal disorders, known hypersensitivity to flunarizine or excipients, and severe hepatic insufficiency.

The drug is prescription‑only in markets where it is approved and use in the UK frequently requires unlicensed‑medicine procedures.

Adverse Effects

What Side Effects Are Most Common?

Common mild adverse effects include drowsiness, weight gain, increased appetite and nasal congestion.

Moderate‑severity effects include fatigue, depressive symptoms, extrapyramidal features (tremor, rigidity, akathisia), gastrointestinal upset and muscle pain.

Overdose produces profound drowsiness, hypotonia and extrapyramidal signs; management is supportive as there is no specific antidote.

Stop flunarizine immediately if new or progressive depression or parkinsonian signs develop.

Interaction Mapping

Food Interactions

Any Dietary Advice?

There are no specific food interactions documented in the product information.

Patients should be counselled to avoid alcohol and other central nervous system depressants because of additive sedation.

Advice on diet and exercise is sensible to counter the risk of weight gain during treatment.

Drug Combinations To Avoid

Which Drug Combinations Increase Risk?

Flunarizine is hepatically metabolised, so co‑administration with strong CYP inhibitors or inducers may change plasma levels; monitor when combinations are unavoidable.

Avoid combining flunarizine with other dopamine‑blocking drugs or high‑potency antipsychotics to reduce cumulative parkinsonism risk.

Caution is required with drugs that lower seizure threshold (certain antipsychotics, tricyclics) and when combining with other sedatives such as benzodiazepines or opioid analgesics.

When used with antidepressants monitor mood closely rather than assuming pharmacodynamic antagonism.

Patient Experience Analysis

Survey Data

What Do Patients Say In Audits And Questionnaires?

Specialist clinic audits and patient questionnaires show a recognisable pattern of benefit and harm.

Many patients with vestibular migraine report clinically meaningful reductions in vertigo severity and attack frequency after 6–12 weeks.

Some migraine sufferers record fewer monthly migraine days, though response is variable.

Discontinuation rates are notable because sedation, weight gain and depressive symptoms lead some patients to stop treatment.

Forum Trends

What Themes Appear In Online Communities?

Patient forums and UK migraine communities commonly report initial drowsiness that often improves within 2–4 weeks.

Weight gain and increased appetite are frequently mentioned as troublesome over months of use.

A minority describe emergence of low mood or tremor prompting cessation, and peer advice commonly recommends taking the tablet at night and keeping a headache or vertigo diary.

UK patients sometimes ask about import routes and costs when Sibelium is discussed; clinicians should ensure informed consent and a clear monitoring plan if importation is used.

Distribution And Pricing Landscape

Availability By Country

Where Is Sibelium On The Market?

Flunarizine as Sibelium® is marketed across many European countries and in Canada with 5 mg and 10 mg tablet strengths commonly available.

Generics from manufacturers such as Teva, Zentiva and Medochemie appear in select markets and on some e‑pharmacies.

Some countries list Sibelium® as withdrawn or unregistered, for example Germany and Sweden, and the product is not registered in Australia.

UK‑Specific Access Routes

How Do UK Patients Get Flunarizine?

Sibelium® has been withdrawn in the UK and is not routinely distributed.

Clinicians may obtain flunarizine by specialist importation or via an unlicensed “special” for individual patients after risk assessment and local governance approval.

Pricing varies widely; generics in EU markets are typically inexpensive but imported or special‑order supplies to the UK incur additional costs and pharmacy handling fees.

Prescription status remains Rx and pharmacists must comply with MHRA rules on importation and pharmacovigilance when supplying imported products.

In our online pharmacy, flunarizine is available without a prescription, with discreet delivery to United Kingdom in 5–14 days.

Alternative Options

Comparison Table

Which Alternatives Should Be Considered First?

• Propranolol: First‑line for many migraine patients with good evidence, but contraindicated in asthma and bradycardia.
• Topiramate: Effective for prevention but associated with cognitive effects and teratogenic risk.
• Amitriptyline: Helpful for comorbid tension headache and sleep, but causes anticholinergic effects and sedation.
• Cinnarizine: Similar vestibular action; less evidence for migraine and potential for sedation and weight gain.
• Betahistine: Used for vertigo with better tolerability regarding movement disorders.

Pros And Cons

How Does Flunarizine Compare?

Pros: Flunarizine is effective in many refractory and vestibular migraine cases and offers once‑daily dosing which patients find convenient.

Cons: Its major disadvantages are sedation, weight gain and the risk of depression and parkinsonism, combined with limited routine availability in the UK.

Choice of preventive should be individualised, taking into account comorbidities such as cardio‑respiratory disease or mood disorders, and patient preference.

Regulatory Status

ATC And Classification

What Is The Drug Classification?

Flunarizine is classified under ATC N07CA03, within antivertigo preparations of the nervous system category.

It is regulated as a prescription‑only medicine in countries where it is approved.

Country‑Level Regulatory Snapshot

Which Countries Permit Routine Supply?

Registered markets include Spain, Italy, France, Netherlands, Romania and Poland, and flunarizine is available by prescription in Canada.

Germany, Sweden and the UK list Sibelium as withdrawn or unregistered, and Australia does not have registration.

Where it is available prescribers should follow the local SmPC guidance, contraindications and monitoring recommendations.

In UK practice any use typically requires unlicensed importation with local governance oversight and clear documentation of indications.

Consolidated FAQ

Quick Answers For Clinicians And Patients

• Is flunarizine available on UK NHS? No nationally licensed supply; access may be via importation or specials with local governance and prescribing justification.
• How long before benefit? Expect benefit at 6–12 weeks; assess at 2–3 months and discontinue if no benefit by six months.
• Who should avoid it? People with current or previous depression, Parkinson’s disease, severe liver disease or significant movement‑disorder risk.
• Can elderly people take it? Use caution—start at 5 mg nightly and monitor closely for parkinsonism and cognitive effects.
• Pregnancy and breastfeeding? Avoid if possible due to limited data; seek specialist advice and balance risks.
• How to stop? Gradual discontinuation may be preferable for some patients if adverse effects occur; document reasons and alternative plans.

Visual Guide

Recommended Diagrams

What Images Help Patients And Clinicians?

Include a mechanism infographic showing calcium‑channel blockade, antihistamine and antidopaminergic actions.

Include a dosing flowchart with decision points for initiation, titration, monitoring and discontinuation.

Include a safety heatmap stratifying risk by age and comorbidity.

Include a comparative chart of benefit versus adverse‑effect profiles for flunarizine, propranolol, topiramate and cinnarizine.

Include a patient journey timeline that shows onset of benefit and common timepoints for adverse effects.

Alt Text And Captions

How Should Images Be Labelled For SEO?

Use filenames and captions optimised for search such as flunarizine‑mechanism‑diagram‑UK.png with a caption like “Flunarizine Sibelium UK mechanism and safety”.

Alt text examples: “Flunarizine mechanism—calcium channel blockade reduces neuronal excitability”.

Storage And Transport

Manufacturer Advice

How Should Flunarizine Be Stored?

Store below 25°C in the original packaging and protect from moisture and light.

Do not freeze and keep blister packs or bottles until use to preserve labelling and expiry information.

Special Considerations For Import

What Should UK Importers Know?

Use licensed wholesalers or manufacturers’ authorised distributors where possible and follow MHRA guidance on importing specials.

Ambient transport is acceptable if the cold chain is not required, but avoid prolonged exposure to temperatures above 30°C.

When patients receive imported supplies advise them to keep tablets in original packaging and to report any anomalies.

Pharmacies should record batch numbers and report adverse events via the Yellow Card system.

Guidelines For Proper Use

Prescriber Checklist

What Steps Should Prescribers Follow?

1. Confirm the indication—commonly refractory migraine or vestibular migraine.
2. Screen for depression, Parkinsonism and hepatic disease before starting treatment.
3. Discuss UK availability and whether importation is necessary; obtain local governance sign‑off when required.
4. Start at 10 mg nightly in most adults, consider 5 mg for elderly or high‑risk patients, document baseline weight and mood scores, and plan reviews at 4–8 weeks and three months.
5. Advise clear stopping rules: new or worsening depression, parkinsonian signs, or no benefit at six months.
6. If imported, record batch and expiry details for pharmacovigilance.

Patient Counselling Points

What Should Patients Know Before Starting?

Explain expected timeline—weeks to months—and common effects such as drowsiness and weight gain.

Highlight red‑flag symptoms that require urgent review: persistent low mood, tremor or rigidity.

Advise taking the tablet at night, keeping a headache/vertigo diary, avoiding alcohol and CNS depressants, and reporting mood or movement changes promptly.

Document informed consent and alternative options discussed, plus the follow‑up plan.

Delivery Across United Kingdom

Frequently Asked Practical Questions

How Is A Decision To Use Flunarizine Reached In Practice?

Clinicians usually reserve flunarizine for patients who have not tolerated or not responded to first‑line preventives such as propranolol, topiramate or amitriptyline.

Local governance and documentation are essential if importation or an unlicensed special is required in the UK.

What Monitoring Is Recommended After Starting?

Baseline and periodic mood screening, weight checks and clinical review for early parkinsonian signs are recommended.

Review timelines commonly at four to eight weeks for tolerability and at two to three months for efficacy.

When Should The Drug Be Stopped Immediately?

New or worsening depression, emergence of tremor or rigidity, severe hepatic impairment or lack of benefit by six months are reasons for stopping.

Final Practical Notes For Clinicians

Documentation Is Key.

Record the indication, informed consent, baseline screening results and planned review dates when prescribing flunarizine, particularly for imported supplies.

Report suspected adverse drug reactions via the Yellow Card system and keep batch numbers on file for imported products.

References And Sources

Core product information and market registration data are taken from international drug databases and product summaries that list flunarizine (INN) with ATC code N07CA03 and the dosing, contraindications and safety profile summarised above.

Where routine UK supply is absent the content reflects common clinical practice of importation and specials supply under MHRA guidance.